Uncategorized

Shares of Akero Therapeutics took a hit after the company missed the primary endpoint in a Phase IIb study of efruxifermin in nonalcoholic steatohepatitis.

Maximizing the true potential of Ozempic—and similar drugs—requires a partnership between drug developers, healthcare providers and patients.

The agency is seeking advisers to help it understand the benefits, risks and outcomes associated with digital technologies.

Elevance, formerly known as Anthem, employs nearly 100,000 associates and serves more than 117 million customers, according to the company.

It’s never too early to start planning next year’s corporate travel. Between new technologies in diabetes, cardiology, orthopedics and more, there will be much to discuss at these medtech events.

The Ambient Assist tool provides notes for clinician review within 30 seconds of a completed patient encounter, according to the health technology company.

The order includes an undisclosed timeline and potential additional fines. Illumina, which has been anticipating the decision, maintains the commission does not have jurisdiction over the completed merger.

The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.

Buying Healthmark strengthens the position of Getinge in the U.S., building on two recent acquisitions of sterile reprocessing technology.

The company released a 2024 earnings outlook below Wall Street expectations on Thursday, two days after announcing a new CEO.